longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Alnylam Pharma

ALNY

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 41.34, within the reasonable range, cheaper than 79.69% of the time in the past 1 years, and the industry ranks 51/601, the industry Median -2.34.

41.34xP/E
$239.36Stock price
$5.79Earnings per share
41.34xP/E
Stock price$239.36Earnings per share$5.79

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
80.23x
Typical range
41.34x–1,124.81x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
ARGXUSArgenx
35.91x35.90%$61.58B
ALNYUSAlnylam Pharma
41.34x183.00%$32.03B
BIIBUSBiogen
38.24x30.25%$31.92B
KRYSUSKrystal Biotech
41.27x10.83%$9.97B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.